Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;40(1):26-34.
doi: 10.1080/07357907.2021.1992420. Epub 2021 Oct 26.

Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy

Mona Ariamanesh  1 , Pejman Porouhan  2 , Babak PeyroShabany  3 , Danial Fazilat-Panah  4 , Mansoureh Dehghani  5 , Maryam Nabavifard  6 , Farbod Hatami  7 , Mohammad Fereidouni  8 , James S Welsh  9 , Seyed Alireza Javadinia  6
Affiliations

Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy

Mona Ariamanesh et al. Cancer Invest. 2022 Jan.

Abstract

Objective: To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.

Material and method: 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2 months following vaccination were measured by ELIZA.

Results: Injection site pain and fever were the most common local and systemic side effects. The overall seroconversion rate was 86.9% that was lower in older age, those with hematological malignancies and chemotherapy receivers.

Conclusion: The result of study confirmed the safety and short-term efficacy of inactivated vaccine in patients with malignancies.

Keywords: COVID-19; COVID-19 vaccines; Malignancy; SARS-CoV-2; anticancer treatment; cancer patients.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1.
Figure 1.
Study protocol.
See this image and copyright information in PMC

References

    1. Korompoki E, Gavriatopoulou M, Kontoyiannis DP.. COVID-19 vaccines in patients with cancer – a welcome addition, but there is need for optimization. JAMA Oncol. 2021;7(8):1113–1114. doi:10.1001/jamaoncol.2021.1218. - DOI - PubMed
    1. Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. doi:10.1016/S0140-6736(20)31173-9. - DOI - PMC - PubMed
    1. Taghizadeh-Hesary F, Porouhan P, Soroosh D, PeyroShabany B, Shahidsales S, Keykhosravi B, et al. . COVID-19 in cancer and non-cancer patients. Int J Cancer Manag. 2021;14(4):e110907. doi:10.5812/ijcm.110907. - DOI
    1. Shahidsales S, Aledavood SA, Joudi M, Molaie F, Esmaily H, Javadinia SA.. COVID-19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case-controlled study from Iran. Cancer Rep (Hoboken). 2021;20:e1378. doi:10.1002/cnr2.1378. - DOI - PMC - PubMed
    1. Desai A, Gupta R, Advani S, Ouellette L, Kuderer NM, Lyman GH, et al. . Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies. Cancer. 2021;127(9):1459–1468. doi:10.1002/cncr.33386. - DOI - PubMed

Substances